Laster Wr

1.6k total citations · 1 hit paper
28 papers, 1.2k citations indexed

About

Laster Wr is a scholar working on Molecular Biology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Laster Wr has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Laster Wr's work include Cancer therapeutics and mechanisms (8 papers), Acute Lymphoblastic Leukemia research (8 papers) and Cancer Treatment and Pharmacology (5 papers). Laster Wr is often cited by papers focused on Cancer therapeutics and mechanisms (8 papers), Acute Lymphoblastic Leukemia research (8 papers) and Cancer Treatment and Pharmacology (5 papers). Laster Wr collaborates with scholars based in United States. Laster Wr's co-authors include Schabel Fm, Trader Mw, Griswold Dp, Corbett Th, Skipper He, Montgomery Ja, Linda Simpson‐Herren, Wilcox Ws, Thomson and WP Peters and has published in prestigious journals such as Cancer Research, PubMed and Munich Personal RePEc Archive (Ludwig Maximilian University of Munich).

In The Last Decade

Laster Wr

28 papers receiving 996 citations

Hit Papers

cis-Dichlorodiammineplatinum(II): combination chemotherap... 1980 2026 1995 2010 1980 100 200 300

Peers

Laster Wr
Comparison fields: 5 of 90
  • Oncology 574
  • Molecular Biology 433
  • Pulmonary and Respiratory Medicine 242
  • Surgery 126
  • Cancer Research 125
Replace Griswold Dp with:
Griswold Dp United States
Holland Jf United States
Robert L. Stolfi United States
J F Holland United States
Skipper He United States
A Goldin United States
Von Hoff United States
David H. Kern United States
P. Dodion Belgium
Schabel Fm United States
Griswold Dp United States View profile →
Citations per field, relative to Laster Wr
Laster Wr · 1×
Citations per year, relative to Laster Wr
Laster Wr · 1×

Countries citing papers authored by Laster Wr

Since Specialization
Citations

This map shows the geographic impact of Laster Wr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laster Wr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laster Wr more than expected).

Fields of papers citing papers by Laster Wr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laster Wr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laster Wr. The network helps show where Laster Wr may publish in the future.

Co-authorship network of co-authors of Laster Wr

This figure shows the co-authorship network connecting the top 25 collaborators of Laster Wr. A scholar is included among the top collaborators of Laster Wr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laster Wr. Laster Wr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.
20
2
Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
25
3
Establishment of cross-resistance profiles for new agents.
92
4
Reversal of methotrexate toxicity in mice by a calcium salt of citrovorum factor and related compounds.
3
5
cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. breakdown →
357
6
Concepts for controlling drug-resistant tumor cells.
43
7
Evaluation of whole-body hyperthermia as an adjunct to chemotherapy in murine tumors.
23
8
Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
7
9
Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU.
3
10
Experimental studies of the antitumor activity of amygdalin MF (NSC-15780) alone and in combination with beta-glucosidase (NSC-128056).
15
11
Basic and therapeutic trial results obtained in the spontaneous AK leukemia (lymphoma) model-end of 1971.
23
12
Success and failure in the treatment of solid tumors. 3. "Cure" of metastatic Lewis lung carcinoma with methyl-CCNU (NSC-95442) and surgery-chemotherapy.
23
13
Response to therapy of spontaneous, first passage, and long passage lines of AK leukemia.
23
14
Chemotherapy of leukemia L1210 by 6-mercaptopurine (NSC-755) in combination with 6-methylthiopurine ribonucleoside (NSC-40774).
4
15
Experimental evaluation of potential anticancer agents. XX. Development of immunity to leukemia L1210 in BDF mice and effects of therapy.
11
16
Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors.
35
17
Experimental evaluation of potential anticancer agents. X. A specificity test for distinguishing false positives.
2
18
Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia.
257
19
Experimental evaluation of potential anticancer agents. II. Studies on the growth characteristics, metastases, and drug response of hamster neoplasms of diverse "sites of origin".
7
20
Experimental evaluation of potential anticancer agents. I. Quantitative therapeutic evaluation of certain purine analogs.
23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026